| Metric | This Period | Prior Year Same Period | YoY |
|---|---|---|---|
| Revenue | ¥183.3B | ¥176.2B | +4.0% |
| Operating Income | ¥45.8B | ¥43.8B | +4.5% |
| Equity-method Investment Income (Loss) | - | - | - |
| Ordinary Income | ¥45.5B | ¥44.2B | +3.0% |
| Net Income | ¥30.5B | ¥29.6B | +3.1% |
| ROE | 10.0% | 10.5% | - |
For the cumulative Q3 period of FY2026 (9 months), Revenue was ¥183.3B (YoY +¥7.1B +4.0%), Operating Income was ¥45.8B (YoY +¥2.0B +4.5%), Ordinary Income was ¥45.5B (YoY +¥1.3B +3.0%), and Net Income was ¥30.5B (YoY +¥0.9B +3.1%), achieving year-over-year increases in both top and bottom lines. Growth was driven by volume expansion and gross margin improvement in the Active Pharmaceutical Ingredient (API) Sales Business, with an Operating Margin maintained at a high level of 25.0% (YoY +0.1pt). However, a foreign exchange loss of ¥0.6B caused a slight drag on profitability at the Ordinary Income stage. Progress versus the full-year forecast stands at Revenue 71.3%, Operating Income 84.3%, Net Income 83.8%, indicating profit progress is ahead of top-line. Gross margin improvements and expense efficiencies suggest upside risk to the full-year forecast.
[Revenue] Revenue of ¥183.3B (YoY +4.0%) was led by the core API Sales Business, which expanded solidly to ¥122.5B (+4.4%). On an external sales basis, the API Sales Business accounted for ¥113.1B and a 61.7% revenue mix. The Pharmaceutical Manufacturing & Sales Business recorded ¥70.2B (+2.1%) with a 38.3% mix. Excluding intersegment transactions on an external sales basis, both segments maintained revenue growth. Gross margin expanded to 34.6% (up +0.5pt from 34.1% a year earlier), driven by volume effects and product mix improvements. Improvement in cost of sales to 65.4% resulted in Gross Profit of ¥63.4B (from ¥60.0B a year earlier, +5.7%), outpacing revenue growth.
[Profitability] Operating Income of ¥45.8B (YoY +4.5%) reflected gross profit expansion absorbing an increase in SG&A (¥17.6B, +8.8%), resulting in higher operating profit. SG&A ratio rose to 9.6% (from 9.2% a year earlier, +0.4pt), reflecting increased investment-type expenses including R&D of ¥1.1B (0.6% of sales). Operating Margin of 25.0% improved slightly from 24.9% a year earlier (+0.1pt), sustaining a high-profitability profile. Ordinary Income of ¥45.5B (+3.0%) saw non-operating income of ¥0.4B (including ¥0.2B interest on securities) offset by non-operating expenses of ¥0.7B (foreign exchange loss ¥0.6B, interest expense ¥0.1B), narrowing the increase from operating level. Ordinary Income margin fell to 24.8% (from 25.1% a year earlier, -0.3pt). Net Income of ¥30.5B (+3.1%) was stable with an effective tax rate of 33.0% (same as prior year), giving Net Income margin of 16.6% (from 16.8% a year earlier, -0.2pt). Extraordinary income of ¥0.04B (gain on sale of fixed assets) was immaterial, and core business-driven profitability continued. In conclusion, the company achieved revenue and profit growth underpinned by gross margin improvement; excluding FX effects in non-operating items, profitability is on an improving trend.
The API Sales Business reported Operating Income of ¥25.9B (YoY +8.3%) and a margin of 21.1% (up +0.7pt from 20.4%), showing the strongest growth and margin improvement. Segment sales including intersegment transactions were ¥122.5B, with intercompany transfers of ¥9.4B against external sales of ¥113.1B. The Pharmaceutical Manufacturing & Sales Business posted Operating Income of ¥19.3B (-0.1%) broadly flat, maintaining a high margin of 27.5% (down -0.6pt from 28.1%). Sales of ¥70.2B were entirely external with no intersegment transactions. After corporate adjustments, total Operating Income of ¥45.8B comprised 56.5% from API Sales and 42.2% from Pharmaceutical Manufacturing & Sales, indicating a high earnings dependence on the API Sales Business.
[Profitability] Operating Margin of 25.0% reflects Gross Margin of 34.6% (improved +0.5pt) and SG&A ratio of 9.6% (up +0.4pt). ROE of 10.0% is driven by Net Income margin 16.6% × Total Asset Turnover 0.48x × Financial Leverage 1.25x, maintaining double-digit capital efficiency. R&D ratio of 0.6% is low for a pharmaceutical company, reflecting a business model centered on API Sales.
[Cash Quality] Days Sales Outstanding (DSO) 76 days, Inventory Turnover Days 119 days, Days Payable Outstanding (DPO) 29 days give a Cash Conversion Cycle of 166 days. Inventory of ¥27.8B increased +30.6% YoY, showing deterioration in inventory turnover efficiency.
[Investment Efficiency] Total Asset Turnover 0.48x (annualized 0.64x) is in line with prior year. Of Tangible Fixed Assets ¥104.7B, Construction-in-Progress is ¥47.2B (45.1% of the total), indicating significant projects awaiting commissioning.
[Financial Soundness] Equity Ratio 80.2% (up +2.3pt from 77.9% prior year), D/E ratio 0.25x, Net D/E ▲0.21x indicate an extremely solid financial base. Current Ratio 421.9%, Quick Ratio 376.0% show ample short-term liquidity. Cash and Deposits ¥132.7B are 6.4x short-term borrowings of ¥20.8B, indicating abundant on-hand liquidity.
On operating activities, Net Income of ¥30.5B and minimal non-operating/extraordinary items indicate continued core-business-driven cash generation. Working capital improved in receivables: Accounts receivable ¥38.1B (including electronic recorded receivables ¥41.2B total ¥79.3B, decreased ¥2.4B YoY). However, the notable build-up in inventory to ¥27.8B (+¥6.5B, +30.6%) was pronounced, with breakdown showing raw materials ¥6.5B (+¥0.5B), work-in-process ¥4.8B (▲¥0.6B), and finished goods ¥27.7B (+¥6.5B), highlighting an increase in finished goods inventory. Trade payables decreased to ¥14.9B from ¥16.0B a year earlier, and DPO shortened to 29 days. As a result, working capital increased, posing a headwind to operating cash generation. In investing activities, Construction-in-Progress rose sharply to ¥47.2B (from ¥32.4B, +45.6%), accelerating capital expenditure. Investment securities also rose significantly to ¥16.6B (from ¥0.9B, +¥15.8B), suggesting stronger strategic investments or surplus cash management. In financing activities, short-term borrowings ¥20.8B (from ¥8.6B, +142.1%) and long-term borrowings ¥10.5B (of which ¥3.0B due within one year) totaled ¥31.3B, up from ¥15.9B (+96.9%), increasing interest-bearing debt. Nevertheless, considering cash on hand of ¥132.7B, Net Debt is ▲¥101.4B, maintaining an effectively debt-free position. Retained earnings increased to ¥281.1B from ¥257.3B (+¥23.7B), showing accumulation of internal reserves.
Most of Ordinary Income ¥45.5B is derived from Operating Income ¥45.8B, indicating a solid recurring earnings base. Non-operating income ¥0.4B mainly comprised ¥0.2B interest on securities and ¥0.2B foreign exchange gains, with stable scale and composition. Non-operating expenses ¥0.7B consisted mainly of ¥0.6B foreign exchange losses and ¥0.1B interest expense; the FX loss appears to be a one-off factor but reduced ordinary-stage margin by 0.3pt in the period. Extraordinary income ¥0.04B (gain on sale of fixed assets) was immaterial. Comprehensive Income ¥30.5B essentially matches Net Income ¥30.5B, with Other Comprehensive Income ▲¥0.05B (valuation difference on securities ▲¥0.1B, deferred hedge gains +¥0.1B) small, so there is no meaningful divergence between comprehensive income and net income. Effective tax rate 33.0% is unchanged from the prior year with no tax anomalies observed; the tax base appears sound. The rapid inventory increase (+30.6%) suggests accrual expansion on the accounting side and warrants attention to year-end inventory valuation and conservative revenue recognition timing, but there is no evidence of excessive profit-frontloading risk.
Full-year forecast: Revenue ¥257.0B (YoY +10.4%), Operating Income ¥54.3B (+1.4%), Ordinary Income ¥54.3B (+1.0%), Net Income ¥36.4B (prior-year comparison not disclosed). Progress through cumulative Q3 stands at Revenue 71.3%, Operating Income 84.3%, Ordinary Income 83.8%, Net Income 83.8%, with profit progress approximately 9pt above the standard 75%. Revenue progress lags the standard by ▲3.7pt, but gross margin improvement and expense control have led operating profitability to outperform plan. The full-year Operating Income forecast of +1.4% is predicated on a smaller increase than Q3’s +4.5%, implying possible assumptions of higher costs or weaker Q4 revenue; however, if current margin trends persist there is upside risk. Dividend forecast is annual ¥18 per share (payout ratio 20.8% against forecast EPS ¥86.42), with no interim dividend revision.
Annual dividend forecast ¥18 implies a payout ratio of 20.8% against forecast EPS ¥86.42, representing a conservative level. Based on outstanding shares of 42,119 thousand (excluding 1 thousand treasury shares), annual dividend payment is approximately ¥760M, and the company has sufficient capacity to pay given Net Income ¥30.5B (9-month cumulative) and cash ¥132.7B. Prior-year same period had ¥0 dividends, so YoY comparison is not possible, but the full-year dividend policy appears oriented toward stable payout. No share buyback disclosure has been made; shareholder returns are dividend-centric. The payout ratio of 20.8% is low versus industry norms and suggests preference for growth investment (Construction-in-Progress ¥47.2B, Investment Securities ¥16.6B). Given retained earnings of ¥281.1B and low payout, there is scope for future dividend increases, but the company is currently prioritizing growth investments.
Inventory stagnation risk: Rapid increase in Inventory to ¥27.8B (YoY +30.6%) and prolonged Inventory Turnover Days of 119 raise the risk of valuation losses from demand fluctuation or obsolescence. The build-up of finished goods inventory is notable, and accuracy of sales planning and inventory management will affect cash flow and margins.
Investment project execution risk: Construction-in-Progress at ¥47.2B (45.1% of tangible fixed assets) remains high; delays in commissioning or budget overruns could pressure margins via unexpected depreciation increases or poor fixed-cost absorption. Transparency around timing and returns of investments is critical.
Foreign exchange risk: The FX loss of ¥0.6B this period demonstrates that foreign-currency transactions and valuation of foreign-denominated assets/liabilities can cause volatility in Ordinary Income. If the API Sales Business has a high international transaction ratio, FX movements may directly affect profitability and cash flow.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 25.0% | 3.2% (1.7%–4.9%) | +21.8pt |
| Net Margin | 16.6% | 2.7% (1.3%–6.0%) | +13.9pt |
Profitability substantially exceeds the industry median, placing the company in the upper group for both Operating and Net Margins.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | 4.0% | 5.0% (-5.0%–7.8%) | -1.0pt |
Revenue growth is slightly below the industry median but remains within the IQR, indicating a standard growth pace.
※ Source: Company aggregation
High-profitability profile and front-loaded profit progress: Operating Margin 25.0% exceeds industry median 3.2% by 21.8pt, with Gross Margin improvement to 34.6% continuing. Full-year profit progress at 84.3% substantially exceeds the standard 75%, suggesting upside remains even if Q4 expenses increase. API Sales Business profit growth of +8.3% is driving the company and supports a robust earnings base.
Monitoring working capital efficiency and investment progress: Rapid Inventory increase (+30.6%) and prolonged Inventory Turnover Days of 119 suppress operating cash generation. High Construction-in-Progress ¥47.2B (45.1% of tangible fixed assets) supports future capacity expansion but the timing of commissioning and investment returns will affect medium-term profitability. Inventory reduction and commissioning progress are key to improving Free Cash Flow and enhancing shareholder return capacity.
Financial strength and scope for dividend increases: Equity Ratio 80.2%, Net D/E ▲0.21x, and cash ¥132.7B indicate an extremely strong financial base. Payout Ratio 20.8% is low and retained earnings ¥281.1B are ample, suggesting meaningful scope for dividend increases or enhanced shareholder returns. The company is currently prioritizing growth investment, but a review of returns policy is expected after projects are commissioned.
This report is an AI-generated earnings analysis based on XBRL financial statement data. It is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the company from public financial statements. Investment decisions are your responsibility; consult a professional if necessary.